← Browse by Condition
Medical Condition
advanced gastric or gastroesophageal junction adenocarcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3, Phase 2
NCT07284134 Phase 3
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Enrollment
560 pts
Location
China
Sponsor
Shanghai Junshi Bioscience Co....
NCT05585580 Phase 2
Recruiting
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Enrollment
59 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ...